Cargando…
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
BACKGROUND: Data on vaccine immunogenicity against SARS-CoV-2 are needed for the 40 million people globally living with HIV who might have less functional immunity and more associated comorbidities than the general population. We aimed to explore safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD...
Ejemplares similares
-
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
por: Ogbe, Ane, et al.
Publicado: (2022) -
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
por: Fidler, Sarah, et al.
Publicado: (2022) -
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
por: Flaxman, Amy, et al.
Publicado: (2021) -
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
por: Marchevsky, Natalie Gabrielle, et al.
Publicado: (2022) -
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
por: Voysey, Merryn, et al.
Publicado: (2023)